Rayner
Alan Hemmant has a diverse work experience background. Alan began their career as a Trainee Solicitor at Gaby Hardwicke Solicitors in September 2006 and completed their training by August 2008. Alan then joined Rix & Kay Solicitors LLP in September 2008 as a Solicitor, where they handled various corporate and commercial issues, focusing on intellectual property. Alan managed due diligence exercises for significant M&A transactions and was involved in negotiating and drafting commercial agreements. After four years with Rix & Kay, Alan joined the University of Sussex in January 2013 as a Solicitor / Research Contracts Officer. While at the university, they served as a senior in-house counsel responsible for drafting, reviewing, and negotiating a wide range of commercial contracts related to research. Alan provided clear and pragmatic advice on multi-jurisdictional issues for international projects. In 2015, Alan transitioned to Rayner, where they started as a Legal Counsel and eventually became the General Counsel, starting in July 2022. Alan'swork at Rayner is ongoing, and details about the specific role responsibilities have not been provided.
Alan Hemmant's education history is as follows:
From 1993 to 1998, they attended St Richard's R.C School, although no degree or field of study is specified.
In 2001, they enrolled at the University of Sussex and obtained an LLB degree in Law with a 2:1 classification in 2004.
From 2004 to 2005, they attended The College of Law, London, where they completed a Legal Practice Course, receiving a commendation.
In 2010 and 2011, they pursued further education at Queen Mary University of London, earning a PG CERT in Trade Mark Law & Practice.
Lastly, from 2012 to 2014, they attended Nottingham Law School, completing the ITMA Intensive Trade Mark Attorney Course, specializing in Trade Mark Law.
This person is not in any offices
Rayner
5 followers
Rayner designs and manufactures intraocular lenses and proprietary injection devices for use in cataract surgery. When Sir Harold Ridley designed the world’s first IOL in 1949, he chose Rayner to manufacture this ground-breaking invention.With more than 65 years of continuous growth and experience, we remain at the forefront of innovation. Weare focused on providing the best IOLs for clinicians and patients and are driven by science to improve patient outcomes and safety.Primary IOLs Our FDA-approved C-flex aspheric (aberration-neutral) monofocal IOL, as well as our toric and multifocal IOL families are now complemented by the RayOne fully preloaded monofocal IOL injection system. Supplementary IOLsDesigned to be implanted in the ciliary sulcus, Rayner Sulcoflex Pseudophakic Supplementary IOLs are available as aspheric, toric, multifocal and multifocal lenses, and offer a reversible solution for correcting residual post-operative refractive errors following the implantation of a conventional IOL in the capsular bag.OVDsOur Ophteis range offers a full spectrum of OVDs from dispersive to cohesive, enabling surgeons to select the OVD best suited to each specific cataract procedure. Ophteis FR Pro with sorbitol -- designed to deliver a new level of corneal endothelial protection from phaco induced trauma -- is the flagship product of Rayner’s ‘Ophteis’ OVD suite. PharmaceuticalsAlthough the intraocular lens plays a leading role in the visual outcomes of cataract and refractive surgery, the pharmaceuticals that manage the tear film and inflammation are critical to the end result. For that reason, Rayner recently acquired the business of Moorfields Pharmaceuticals. The acquisition will enable us to offer an even wider range of ophthalmic tools that aid and streamline the surgical process whilst remaining focused on the visual outcome for the patient.Rayner markets its IOL portfolio and related products worldwide through a network of distributors in over 80 countries with direct markets in UK, Germany & Austria, the United States of America, Italy and Spain. We have the world’s longest commercial history of IOL design and manufacturing and have worked with cataract surgeons for longer than anyone else.In 2016, Rayner transferred its global headquarters to a brand new state of the art manufacturing plant, which has dramatically increased the company’s production capacity.